Chronic kidney disease now affects nearly 850 million people worldwide, yet early detection and simple, evidence-based interventions can dramatically change the trajectory of both kidney and cardiovascular health. 🌍🩺
The latest Lancet Seminar highlights powerful tools—eGFR + albuminuria staging, SGLT2 inhibitors, RAS blockade, statins, and GLP-1 therapies—that allow every clinician to make a measurable impact. 💊📉
A reminder that timely action is kidney protection. 💧✨
